Poniard Pharmaceuticals Announces Picoplatin Safety Data In Colorectal Cancer
Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on oncology, announced that it has presented safety data from a Phase 1 dose-escalation study of picoplatin, the Company’s lead product candidate, at the 2008 Gastrointestinal Cancers Symposium, a meeting of the American Society of Clinical Oncology (ASCO) which is being held in Orlando, Fla.
More: continued here
Filed under: Clinical Trials on January 29th, 2008